Literature DB >> 28870399

The risk of reoperative cardiac surgery in radiation-induced valvular disease.

Julius I Ejiofor1, Fernando Ramirez-Del Val1, Anju Nohria2, Anthony Norman1, Siobhan McGurk1, Sary F Aranki1, Prem Shekar1, Lawrence H Cohn1, Tsuyoshi Kaneko3.   

Abstract

OBJECTIVE: Mediastinal radiation therapy (MRT) increases the risk for adverse outcomes after cardiac surgery and is not incorporated in the Society of Thoracic Surgeons (STS) risk algorithm. We aimed to quantify the surgical risk conferred by MRT in patients undergoing primary and reoperative valvular operations.
METHODS: A retrospective analysis of 261 consecutive patients with prior MRT who underwent valvular operations between January 2002 and May 2015. Short- and long-term outcomes were compared for STS predicted risk of mortality, surgery type, gender, year of surgery, and age-matched patients stratified by reoperative status.
RESULTS: Mean age was 62.6 ± 12.1 years and 174 (67%) were women. The majority had received MRT for Hodgkin lymphoma (48.2%) and breast cancer (36%). Overall, 214 (82%) were primary and 47 (18%) were reoperative procedures. Reoperation carried a higher operative mortality than primary cases (17% vs 3.7%; P = .003). Compared with the 836 nonradiated matches, operative mortality and observed-to-expected STS mortality ratios were higher in primary (3.8% [1.4] vs 0.8% [0.32]; P = .004) and reoperative (17% [3.35] vs 2.3% [0.45]; P = .001) patients with prior MRT. Cox proportional hazard modeling revealed that in patients with previous MRT, primary (hazard ratio, 2.24; 95% confidence interval, 1.73-2.91) and reoperative status (hazard ratio, 3.19; 95% confidence interval, 1.95-5.21) adversely affected long-term survival compared with nonradiated matches.
CONCLUSIONS: Surgery for radiation-induced valvular heart disease has a higher operative mortality than predicted by STS predicted risk of mortality. Reoperations are associated with increased morbidity and mortality compared with primary cases. Careful patient selection is paramount and expanded indications for transcatheter therapies should be considered, especially in reoperative patients.
Copyright © 2017 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  mediastinal radiotherapy; radiation-induced valvular heart disease; reoperative valve surgery; valvular heart disease

Mesh:

Year:  2017        PMID: 28870399     DOI: 10.1016/j.jtcvs.2017.07.033

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

Review 1.  Pregnancy Among Survivors of Childhood Cancer: Cardiovascular Considerations.

Authors:  Michael C Honigberg; Amy A Sarma
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-06-19

2.  Recommendations for Preoperative Assessment and Shared Decision-Making in Cardiac Surgery.

Authors:  Maks Mihalj; Thierry Carrel; Richard D Urman; Frank Stueber; Markus M Luedi
Journal:  Curr Anesthesiol Rep       Date:  2020-03-04

Review 3.  Cardio-oncology discipline: focus on the necessities in developing countries.

Authors:  Azin Alizadehasl; Ahmad Amin; Majid Maleki; Feridoun Noohi; Ardeshir Ghavamzadeh; Melody Farrashi
Journal:  ESC Heart Fail       Date:  2020-06-30

4.  Transcatheter Compared With Surgical Aortic Valve Replacement in Patients With Previous Chest-Directed Radiation Therapy.

Authors:  Farhang Yazdchi; Sameer A Hirji; Anju Nohria; Edward Percy; Morgan Harloff; Alexandra Malarczyk; Paige Newell; Mariam B Kerolos; Siobhan McGurk; Prem Shekar; Pinak Shah; Tsuyoshi Kaneko
Journal:  JACC CardioOncol       Date:  2021-09-21

Review 5.  Mediastinal irradiation and valvular heart disease.

Authors:  Shivaraj Patil; Srinath-Reddi Pingle; Khalid Shalaby; Agnes S Kim
Journal:  Cardiooncology       Date:  2022-04-08

6.  Outcomes of cardiac surgery after mediastinal radiation therapy: A single-center experience.

Authors:  Onur B Dolmaci; Emile S Farag; S Matthijs Boekholdt; Wim J P van Boven; Abdullah Kaya
Journal:  J Card Surg       Date:  2020-01-23       Impact factor: 1.620

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.